Hypertriglyceridemia: a possible diagnostic marker of disease severity in visceral leishmaniasis

Infection

Volumn 44, Issue 1, 2016, Pages 39-45

  Lal, C S ^a   Verma, R B ^a   Verma, N ^a   Siddiqui, N A ^a   Rabidas, V N ^a   Pandey, K ^a   Singh, D ^a   Kumar, S ^a   Paswan, R K ^a   Kumari, A ^a   Sinha, P ^a   Das, P ^a  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anemia; Severity; Triglyceride; Visceral leishmaniasis

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; BIOLOGICAL MARKER;

ADULT; ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PARASITE LOAD; PROGNOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; BLOOD; CASE CONTROL STUDY; LEISHMANIASIS, VISCERAL; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PARASITE LOAD; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84964240712     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0811-9     Document Type: Article

References (36)

1. WHO. Control of the Leishmaniasis. Geneva: WHO (Technil Report Series 949); 2010. p. 104.
2. Van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin Clin North Am. 2012;26:309–22.
3. Lukes J, Schorian G, Dujardin JC, et al. Evolutionary and geographical history of the Leishmania donovani complex with a rvision of current taxonomy. Proc Natl Acad Sci USA. 2007;104:9375–80.
4. Alwar J, Velez ID, Burn C, et al. The WHO Leishmaniasis control team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
5. Das P, Samuels S, Desjeux P, et al. Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India. Trop Med Int Health. 2010;15:4–11.
6. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determination of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004;38:612–9.
7. Leishmaniasis and HIV coinfection. http://www.who.int/leishmaniasis/burden/hiv_coinfection/burden_hiv_coinfection/en/. Accessed 19 May 2015.
8. Kala-azar or Visceral Leishmaniasis. National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare, Govt. of India. http://www.nvbdcp.gov.in/Kal4.html. Accessed 19 May 2015.
9. World Health Organization. Report of the 5th consultative meeting on Leishmania/HIV co-infection. WHO; 2007.
10. Bhattacharya SK, Sur D, Karbwang J. Childhood visceral leishmaniasis. Ind J Med Res. 2006;123:353–6.
11. Sarkar CB, Alam KS, Jamal MF, et al. Sensitivity of splenic and bone marrow aspirate study for diagnosis of kala azar. Mymensingh Med J. 2004;13:130–3.
12. Jetley S, Rana S, Khan S, et al. Bone marrow negative Visceral leishmaniasis in an adolescent male. Iran J Parasitol. 2013;8:182–5.
13. Cunningham J, Hasker E, Das P, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Inf Dis. 2012;55:1312–9.
14. Goswami RP, Bairagi B, Kundu PK. K39 strip test-Easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India. J Assoc Physicians India. 2003;51:759–61.
15. Kyrtatos PG, Debard A, Martin-Blondel G, et al. FDG-PET/CT findings during immune reconstitution in an HIV-1 patient infected with visceral leishmaniasis. Infection. 2013;41:1017–9.
16. Bertoli A, Greco AV, Caputo S, et al. Visceral leishmaniasis presenting with hypertriglyceridaemia. Lancet. 1982;8296:504–5.
17. Mebazaa A, Kallel R, Boussen H, et al. Perturbations des lipids lipoproteins seriques au cours du kala-azar. Tunis Med. 1984;62:149–51.
18. Bekaert ED, Kallel R, Bouma M-E, et al. M. Plasma lipoproteins in infantile visceral leishmaniasis: deficiency of apolipoproteins A-I and A-II. Clin Chim Acta. 1989;184:181–92.
19. Malmendier CL, Lontie JF, Dubois DY. Mechanisms of hypocholesterolemia. Adv Exp Med Biol. 1991;285:173–82.
20. Bekaert ED, Dole E, Dubois DY, et al. Alterations in lipoprotein density classes in infantile visceral leishmaniasis: presence of apolipoproteins SAA. Eur J Clin Investig. 1992;10:190–9.
21. Kallel R, Bekaert ED, Dubois DY, et al. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis. Clin Physiol Biochem. 1993;10:8–12.
22. Liberopoulos E, Alexandridis G, Bairaktari E, et al. Severe hypocholesterolemia with reduced lipoprotein (a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci. 2002;32:305–8.
23. Lal CS, Kumar A, Kumar S, et al. Hypocholesterolemia and increased triglyceride in pediatric visceral leishmaniasis. Clin Chim Acta. 2007;382:151–3.
24. Lal CS, Verma N, Rabidas VN, et al. Total serum cholesterol determination can provide understanding of parasite burden in patients with visceral leishmaniasis infection. Clin Chim Acta. 2010;411:2112–3.
25. Ghosh J, Lal CS, Pandey K, et al. human visceral leishmaniasis: decrease in serum cholesterol of Kala-azar patients as a function of splenic parasite load. Annals Trop Med Parasitol. 2011;105:267–71.
26. Erdeve O, Dallar Y, Siklar Z. Is hypertriglyceridemia a new concept for visceral leishmaniasis? Ann Trop Paediatr. 2004;24:369.
27. Secmeer G, Cengiz AB, Gurgey A, et al. Hypertriglyceridemia and decreased high density lipoprotein could be a clue for visceral leishmaniasis. Infect Dis Clin Pract. 2006;14:401–2.
28. Mohapatra S, Samantaray JC, Dash S, et al. Lipid derangement as diagnostic and prognostic indicator for visceral leishmaniasis. Trop Parasitol. 2014;4:134–5.
29. de Benoist B, Mclean E, Egli I, Cogswell M. Worldwide prevalence of anemia 1993–2005 WHO Global database on anemia. 2nd ed. Geneva: WHO; 2008.
30. Chulay JD, Bryceson ADM. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg. 1983;32:475–9.
31. Muniaraj M, Kumar S, Lal CS, et al. Biochemical profile of Milk of Buffalo (Bubalus bubalis), Cow (Bos taurus) and Goat (Capra hircus): potential candidates for supporting the growth of Leishmania donovani promastigotes in culture medium as alternative to fetal bovine serum (FBS). J Buffalo Sci. 2012;1:174–6.
32. Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181:S462–72.
33. Nanjee MN, Cooke CJ, Olszewski WL, Miller NE. Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency. J Lipid Res. 2000;41:1317–27.
34. Soares NM, Leal TF, Fiuza MC, et al. Plasma lipoproteins in visceral leishmaniasis and their effect on leishmania-infected macrophages. Parasite Immunol. 2010;32:259–66.
35. Parola P, Gazin P, Patella F, et al. Hypertriglyceridemia as an indicator of the severity of falciparum malaria in returned travelers: a clinical retrospective study. Parasitol Res. 2004;92:464–6.
36. Mizock BA. Metabolic derangements in sepsis and septic shock. Crit Care Clin. 2009;16:319–36.